Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuo Therapeutics, Inc.AURX · Entity 7149 | Director · 10% owner | October 06, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuo Therapeutics, Inc.
Report date October 06, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Second Restated Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2031-01-23 | Direct | 4,500 |
Reported balance
After 2026-10-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 4,500 · Balance 4,500 F1: Represents Commitment, Origination Restated Second, and Capital Restate Second Warrants issued in connection with the assumption of a portion of an assigned funding commitment pursuant to the Assignment, Joinder, and Amendment No. 1 dated October 6, 2026 among the Issuer, the Reporting Person, and the other parties thereto (the "Amendment"), relating to the Amended and Restated Loan and Security Agreement dated May 29, 2026 (the "Loan Agreement"). The Reporting Person also holds a previously reported separate Second Restated Warrant that was issued and become exercisable on May 29, 2026. |
| Prepayment Restated Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2031-01-23 | Direct | 458 |
Reported balance
After 2026-10-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 458 · Balance 458 F2: Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement, issued in connection with the assumption of a portion of an assigned commitment pursuant to the Amendment. The Reporting Person also holds a previously-reported separate Prepayment Restated Warrant that was issued on May 29, 2026, subject to the same vesting provision set forth in footnote (3) immediately below. F3: Vesting (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2027, in accordance with the Loan Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Commitment, Origination Restated Second, and Capital Restate Second Warrants issued in connection with the assumption of a portion of an assigned funding commitment pursuant to the Assignment, Joinder, and Amendment No. 1 dated October 6, 2026 among the Issuer, the Reporting Person, and the other parties thereto (the "Amendment"), relating to the Amended and Restated Loan and Security Agreement dated May 29, 2026 (the "Loan Agreement"). The Reporting Person also holds a previously reported separate Second Restated Warrant that was issued and become exercisable on May 29, 2026.
F2: Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement, issued in connection with the assumption of a portion of an assigned commitment pursuant to the Amendment. The Reporting Person also holds a previously-reported separate Prepayment Restated Warrant that was issued on May 29, 2026, subject to the same vesting provision set forth in footnote (3) immediately below.
F3: Vesting (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2027, in accordance with the Loan Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 6, 2026 22:11 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantPrepayment Restated Warrant (right to buy) · Derivative | 458 | $1.50 Strike: $1.50 | $687.00 |
DisclosureSEC source: 0001437749-26-032249 · rdgdoc.xml · derivative · entry 2 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 458 Underlying: Common Stock · 458 shares Expires 2031-01-23 F2 · security: Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement, issued in connection with the assumption of a portion of an assigned commitment pursuant to the Amendment. The Reporting Person also holds a previously-reported separate Prepayment Restated Warrant that was issued on May 29, 2026, subject to the same vesting provision set forth in footnote (3) immediately below. F3 · derivative.exercise_date: Vesting (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2027, in accordance with the Loan Agreement. Read SEC document |
| October 06, 2026 Filed Oct 6, 2026 22:11 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantSecond Restated Warrant (right to buy) · Derivative | 4,500 | $1.50 Strike: $1.50 | $6,750.00 |
DisclosureSEC source: 0001437749-26-032249 · rdgdoc.xml · derivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2031-01-23 F1 · security: Represents Commitment, Origination Restated Second, and Capital Restate Second Warrants issued in connection with the assumption of a portion of an assigned funding commitment pursuant to the Assignment, Joinder, and Amendment No. 1 dated October 6, 2026 among the Issuer, the Reporting Person, and the other parties thereto (the "Amendment"), relating to the Amended and Restated Loan and Security Agreement dated May 29, 2026 (the "Loan Agreement"). The Reporting Person also holds a previously reported separate Second Restated Warrant that was issued and become exercisable on May 29, 2026. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 01:00 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionOption to purchase common stock · Derivative | 40,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022664 · rdgdoc.xml · derivative · entry 3 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2026-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 15,000 options exercisable on 07/01/2016 and 25,000 options exercisable on 01/01/2017. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 01:00 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Tax withholdingCommon Stock | 39,604 | $1.01 | $40,000.04 |
DisclosureSEC source: 0001437749-26-022664 · rdgdoc.xml · nonDerivative · entry 2 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,400,396 F1 · kind: Represents a net exercise of outstanding stock options. The reporting person received 396 shares of common stock on the net exercise of option to purchase 40,000 shares of common stock. The issuer withheld 39,604 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01. Read SEC document |
| June 30, 2026 Filed Jul 3, 2026 01:00 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionCommon Stock | 40,000 | $1.00 | $40,000.00 |
DisclosureSEC source: 0001437749-26-022664 · rdgdoc.xml · nonDerivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,440,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jul 3, 2026 01:00 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to purchase common stock · Derivative | 30,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001437749-26-022664 · rdgdoc.xml · derivative · entry 4 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-29 F3 · derivative.exercise_date: The options fully vest as of June 30, 2027. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 01:54 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantPrepayment Restated Warrant (right to buy) · Derivative | 7,333 | $1.50 Strike: $1.50 | $10,999.50 |
DisclosureSEC source: 0001437749-26-019246 · rdgdoc.xml · derivative · entry 5 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,333 shares Expires 2031-01-23 F2 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F5 · kind: Previously issued Prepayment Warrants cancelled for Prepayment Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Loan Agreement. F7 · shares: Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement. F8 · derivative.exercise_date: Vesting (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 01:54 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantSecond Restated Warrant (right to buy) · Derivative | 17,500 | $1.50 Strike: $1.50 | $26,250.00 |
DisclosureSEC source: 0001437749-26-019246 · rdgdoc.xml · derivative · entry 4 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2031-01-23 F2 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F4 · kind: Previously issued Second Warrants cancelled for Second Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Amended and Restated Loan and Security Agreement dated May 29, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement"). F6 · derivative.exercise_date: Vesting (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan Agreement. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 01:54 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Disposition to issuerPrepayment Warrant (right to buy) · Derivative | 7,516 | $1.50 Strike: $1.50 | $11,274.00 |
DisclosureSEC source: 0001437749-26-019246 · rdgdoc.xml · derivative · entry 3 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,516 shares Expires 2031-01-23 F2 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F5 · kind: Previously issued Prepayment Warrants cancelled for Prepayment Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Loan Agreement. Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 01:54 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Disposition to issuerSecond Warrant (right to buy) · Derivative | 36,750 | $1.50 Strike: $1.50 | $55,125.00 |
DisclosureSEC source: 0001437749-26-019246 · rdgdoc.xml · derivative · entry 2 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,750 shares Expires 2031-01-23 F3 · security: Represents Origination Restated Second and Capital Restated Second Warrants. F2 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F4 · kind: Previously issued Second Warrants cancelled for Second Restated Warrants with same terms, including same exercise price (and cancelled on date when underlying Common Stock traded at lower price than when previously issued), in accordance with the Amended and Restated Loan and Security Agreement dated May 29, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement"). Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 01:54 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantInterim Warrant (right to buy) · Derivative | 17,450 | $1.50 Strike: $1.50 | $26,175.00 |
DisclosureSEC source: 0001437749-26-019246 · rdgdoc.xml · derivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,450 Underlying: Common Stock · 17,450 shares Expires 2031-01-23 F1 · security: Represents Origination Interim and Capital Interim Warrants. F2 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 23:44 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantPrepayment Warrants (right to buy) · Derivative | 7,516 | $1.50 Strike: $1.50 | $11,274.00 |
DisclosureSEC source: 0001437749-26-002128 · rdgdoc.xml · derivative · entry 6 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,516 shares Expires 2031-01-23 F2 · derivative.exercise_date: Will vest (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement. F3 · derivative.underlying_shares: Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement. The Board of Directors of Issuer and Non-Employee Directors approved the Loan Agreement and issuance of warrants and shares of Common Stock issuable thereunder Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 23:44 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCapital Second Warrants (right to buy) · Derivative | 35,000 | $1.50 Strike: $1.50 | $52,500.00 |
DisclosureSEC source: 0001437749-26-002128 · rdgdoc.xml · derivative · entry 5 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2031-01-23 F1 · derivative.exercise_date: Will vest (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan and Security Agreement dated January 21, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement"). Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 23:44 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOrigination Second Warrants (right to buy) · Derivative | 1,750 | $1.50 Strike: $1.50 | $2,625.00 |
DisclosureSEC source: 0001437749-26-002128 · rdgdoc.xml · derivative · entry 4 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires 2031-01-23 F1 · derivative.exercise_date: Will vest (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan and Security Agreement dated January 21, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement"). Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 23:44 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCapital Initial Warrants (right to buy) · Derivative | 26,667 | $1.50 Strike: $1.50 | $40,000.50 |
DisclosureSEC source: 0001437749-26-002128 · rdgdoc.xml · derivative · entry 3 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,667 shares Expires 2031-01-23 Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 23:44 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOrigination Initial Warrants (right to buy) · Derivative | 1,333 | $1.50 Strike: $1.50 | $1,999.50 |
DisclosureSEC source: 0001437749-26-002128 · rdgdoc.xml · derivative · entry 2 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,333 shares Expires 2031-01-23 Read SEC document |
| January 23, 2026 Filed Jan 26, 2026 23:44 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommitment Warrants (right to buy) · Derivative | 2,050 | $1.50 Strike: $1.50 | $3,075.00 |
DisclosureSEC source: 0001437749-26-002128 · rdgdoc.xml · derivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,050 shares Expires 2031-01-23 Read SEC document |
| January 23, 2026 Filed Jun 3, 2026 01:49 UTC Amendment | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantPrepayment Warrant (right to buy) · Derivative | 7,516 | $1.50 Strike: $1.50 | $11,274.00 |
DisclosureSEC source: 0001437749-26-019244 · rdgdoc.xml · derivative · entry 3 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,516 shares Expires 2031-01-23 F4 · shares: Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement. F5 · derivative.exercise_date: Will vest (if at all) upon the occurrence of a Prepayment, but no later than December 31, 2028, in accordance with the Loan Agreement. F4 · derivative.underlying_shares: Represents maximum number of shares issuable (if at all) in the event of a Prepayment in accordance with the Loan Agreement. Read SEC document |
| January 23, 2026 Filed Jun 3, 2026 01:49 UTC Amendment | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantSecond Warrant (right to buy) · Derivative | 36,750 | $1.50 Strike: $1.50 | $55,125.00 |
DisclosureSEC source: 0001437749-26-019244 · rdgdoc.xml · derivative · entry 2 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,750 shares Expires 2031-01-23 F2 · security: This Form 4 amendment corrects the name of warrant issued in the form of an integrated Second Warrant, which represents Origination Second Capital Second Warrants. F3 · derivative.exercise_date: Will vest (if at all) on September 30, 2026 provided a Second Funding occurs in accordance with the Loan and Security Agreement dated January 21, 2026 among the Issuer, the Reporting Person, and other parties thereto (the "Loan Agreement"). Read SEC document |
| January 23, 2026 Filed Jun 3, 2026 01:49 UTC Amendment | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantInitial Warrant (right to buy) · Derivative | 30,050 | $1.50 Strike: $1.50 | $45,075.00 |
DisclosureSEC source: 0001437749-26-019244 · rdgdoc.xml · derivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,050 Underlying: Common Stock · 30,050 shares Expires 2031-01-23 F1 · security: This Form 4 amendment corrects the name of warrant issued in the form of an integrated Initial Warrant, which represents Commitment Initial, Origination Initial, and Capital Initial Warrants immediately exercisable for an aggregate of 30,050 shares of Common Stock. F1 · balance_after: This Form 4 amendment corrects the name of warrant issued in the form of an integrated Initial Warrant, which represents Commitment Initial, Origination Initial, and Capital Initial Warrants immediately exercisable for an aggregate of 30,050 shares of Common Stock. Read SEC document |
| July 30, 2025 Filed Aug 1, 2025 22:07 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 3,946 | $1.50 | $5,919.00 |
DisclosureSEC source: 0001437749-25-024429 · rdgdoc.xml · nonDerivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,400,000 F1 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:51 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionCommon Stock | 33,334 | $0.50 | $16,667.00 |
DisclosureSEC source: 0001437749-24-035771 · rdgdoc.xml · nonDerivative · entry 3 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,396,054 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:51 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionCommon Stock | 62,500 | $0.40 | $25,000.00 |
DisclosureSEC source: 0001437749-24-035771 · rdgdoc.xml · nonDerivative · entry 2 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,362,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:51 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionCommon Stock | 121,875 | $0.40 | $48,750.00 |
DisclosureSEC source: 0001437749-24-035771 · rdgdoc.xml · nonDerivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,300,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2024 Filed Jul 22, 2024 22:55 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to Purchase Common Stock · Derivative | 40,000 | $0.33 Strike: $0.33 | $13,200.00 |
DisclosureSEC source: 0001437749-24-023226 · rdgdoc.xml · derivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-07-17 F1 · derivative.exercise_date: Options fully vest on one year anniversary of grant. Read SEC document |
| May 20, 2024 Filed May 21, 2024 19:11 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 135,000 | $0.75 | $101,250.00 |
DisclosureSEC source: 0001437749-24-017813 · rdgdoc.xml · nonDerivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,178,345 F1 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 19:03 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 600,000 | $0.50 | $300,000.00 |
DisclosureSEC source: 0001437749-23-034980 · rdgdoc.xml · nonDerivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,043,345 F1 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:17 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 100,000 | $2.00 | $200,000.00 |
DisclosureSEC source: 0001437749-23-021946 · rdgdoc.xml · nonDerivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,443,345 F1 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors Read SEC document |
| April 29, 2022 Filed May 2, 2022 16:22 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 100,000 | $1.00 | $100,000.00 |
DisclosureSEC source: 0001437749-22-010379 · rdgdoc.xml · nonDerivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,343,345 F1 · date: Transaction approved by Board of Directors of Issuer and Non-Employee Directors Read SEC document |
| March 04, 2022 Filed Apr 27, 2022 01:31 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to Purchase Common Stock · Derivative | 100,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001437749-22-009787 · rdgdoc.xml · derivative · entry 2 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-03-04 Read SEC document |
| March 04, 2022 Filed Apr 27, 2022 01:31 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to Purchase Common Stock · Derivative | 33,334 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001437749-22-009787 · rdgdoc.xml · derivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 33,334 shares Expires 2032-03-04 F1 · date: Granted in settlement of compensation liability for period January 1, 2019 through April 30, 2019 Read SEC document |
| March 04, 2022 Filed Nov 19, 2024 22:51 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionOption to Purchase Common Stock · Derivative | 33,334 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001437749-24-035771 · rdgdoc.xml · derivative · entry 6 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,334 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 30, 2021 Filed Apr 27, 2022 01:26 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionWarrants to purchase Common Stock · Derivative | 900,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001437749-22-009784 · rdgdoc.xml · derivative · entry 6 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 900,000 shares Expires 2022-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed canceled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price. Read SEC document |
| December 30, 2021 Filed Apr 27, 2022 01:26 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionCommon Stock | 900,000 | $0.20 | $180,000.00 |
DisclosureSEC source: 0001437749-22-009784 · rdgdoc.xml · nonDerivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,243,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2021 Filed Apr 27, 2022 01:26 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | OtherWarrants to purchase Common Stock · Derivative | 322,635 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009784 · rdgdoc.xml · derivative · entry 5 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 322,635 shares Expires 2022-01-31 F5 · kind: Transferred to third party for no consideration Read SEC document |
| December 01, 2021 Filed Apr 27, 2022 01:26 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Disposition to issuerWarrants to purchase Common Stock · Derivative | 322,635 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009784 · rdgdoc.xml · derivative · entry 4 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 322,635 shares Expires 2025-10-05 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F4 · shares: Cancelled in accordance with Warrant Modification Agreement dated as of 12/01/21 F3 · price: The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed canceled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price. Read SEC document |
| December 01, 2021 Filed Apr 27, 2022 01:26 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Disposition to issuerWarrants to purchase Common Stock · Derivative | 900,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009784 · rdgdoc.xml · derivative · entry 3 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 900,000 shares Expires 2025-10-05 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F4 · shares: Cancelled in accordance with Warrant Modification Agreement dated as of 12/01/21 F3 · price: The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed canceled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price. Read SEC document |
| December 01, 2021 Filed Apr 27, 2022 01:26 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantWarrants to purchase Common Stock · Derivative | 1,222,635 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001437749-22-009784 · rdgdoc.xml · derivative · entry 2 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222,635 Underlying: Common Stock · 1,222,635 shares Expires 2022-01-31 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F2 · shares: Acquired in accordance with Warrant Modification Agreement dated as of 12/01/21 F3 · price: The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed canceled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price. Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:23 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantWarrants to purchase Common Stock · Derivative | 900,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009781 · rdgdoc.xml · derivative · entry 6 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2025-10-05 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F9 · shares: Compensation warrants acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:23 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Disposition to issuerWarrants to purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009781 · rdgdoc.xml · derivative · entry 5 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F7 · shares: Cancelled in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 F6 · price: The reported transactions involved a recapitalization resulting in the deemed cancellation of the "old" warrants and the deemed grant of "replacement" warrants. F8 · derivative.exercise_date: Originally exercisable on 11/15/19 and 12/06/19, with expirations of 11/15/24 and 12/06/24, respectively, for 15,000 shares and 30,000 shares F8 · derivative.expiration_date: Originally exercisable on 11/15/19 and 12/06/19, with expirations of 11/15/24 and 12/06/24, respectively, for 15,000 shares and 30,000 shares Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:23 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantWarrants to purchase Common Stock · Derivative | 322,635 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009781 · rdgdoc.xml · derivative · entry 4 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,635 Underlying: Common Stock · 322,635 shares Expires 2025-10-05 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F5 · shares: Acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 F6 · price: The reported transactions involved a recapitalization resulting in the deemed cancellation of the "old" warrants and the deemed grant of "replacement" warrants. Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:23 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 25,000 | $0.40 | $10,000.00 |
DisclosureSEC source: 0001437749-22-009781 · rdgdoc.xml · nonDerivative · entry 3 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,343,345 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F4 · shares: Purchase shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:23 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 82,545 | $0.40 | $33,018.00 |
DisclosureSEC source: 0001437749-22-009781 · rdgdoc.xml · nonDerivative · entry 2 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,318,345 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F3 · shares: Conversion shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 Read SEC document |
| October 05, 2020 Filed Apr 27, 2022 01:23 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantCommon Stock | 300,000 | $0.40 | $120,000.00 |
DisclosureSEC source: 0001437749-22-009781 · rdgdoc.xml · nonDerivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,235,800 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F2 · shares: Compensation shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 Read SEC document |
| December 06, 2019 Filed Apr 27, 2022 01:20 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantWarrants to purchase Common Stock · Derivative | 30,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009778 · rdgdoc.xml · derivative · entry 2 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 30,000 shares Expires 2024-12-06 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F2 · shares: Acquired in connection with Note Purchase Agreement dated as of November 15, 2019 Read SEC document |
| November 15, 2019 Filed Apr 27, 2022 01:20 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantWarrants to purchase Common Stock · Derivative | 15,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-22-009778 · rdgdoc.xml · derivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2024-11-15 F1 · kind: Transaction approved by Board of Directors of Issuer and Non-Employee Directors F2 · shares: Acquired in connection with Note Purchase Agreement dated as of November 15, 2019 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 16:52 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to Purchase Common Stock · Derivative | 62,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001091596-19-000003 · primary_doc.xml · derivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: COMMON STOCK · 62,500 shares Expires 2025-12-31 Read SEC document |
| December 31, 2018 Filed Nov 19, 2024 22:51 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionOption to Purchase Common Stock · Derivative | 62,500 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-24-035771 · rdgdoc.xml · derivative · entry 5 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,500 shares Expires 2025-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 20:20 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | GrantOption to Purchase Common Stock · Derivative | 121,875 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001605411-18-000005 · primary_doc.xml · derivative · entry 1 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,875 Underlying: COMMON STOCK · 121,875 shares Expires 2025-08-09 Read SEC document |
| August 09, 2018 Filed Nov 19, 2024 22:51 UTC | Nuo Therapeutics, Inc. AURX · Entity 7149 | Exercise / conversionOption to Purchase Common Stock · Derivative | 121,875 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001437749-24-035771 · rdgdoc.xml · derivative · entry 4 Pittman Scott M. · CIK 0001674752 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,875 shares Expires 2025-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.